Patent Application
20190374689
The present invention relates generally to systems and methods for improving the battery life of battery-powered devices through hysteresis control. Such battery-powered devices include, without limitation, negative-pressure wound therapy systems.
Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but it has proven particularly advantageous for treating wounds where the system is configured to remove fluid and infectious material from the wound site. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of the wound site is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as “negative-pressure therapy,” but is also known by other names, including “negative-pressure wound therapy,” “reduced-pressure therapy,” “vacuum therapy,” and “vacuum-assisted closure,” for example. Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.
While the clinical benefits of negative-pressure wound therapy are widely known, the provision of negative-pressure wound therapy over a therapeutic life cycle, which can be 7 days or more, is increasingly being performed with small portable disposable therapy devices that are powered by batteries rather than a connection to an electrical outlet. Since, these small portable therapy devices are often disposable and typically use non-rechargeable batteries to avoid adding cost to a disposable unit or a burden to a user by requiring the batteries to be periodically charged, the design of these devices is challenging. Because the limiting factor in many applications is not the ability of their pumps to run harder in the case of a therapeutic dressing with an imperfect seal, but the limited capacity of their batteries under these conditions.
An alternative is therefore needed to either requiring the user to obtain a better seal during dressing application, requiring a new dressing that better accommodates the user and is therefore easier to obtain a seal with, requiring the device to have higher capacity batteries or the user to change or re-charge the batteries, is needed. What is needed is a system level approach to reduce the power consumption over the therapeutic life cycle, at a reasonable cost that does not unduly burden to the user.
While the present invention can be used to improve the battery life of battery-powered devices generally, the description and examples herein primarily focus on negative-pressure wound therapy systems. It is understood by those skilled in the art that the description and examples herein are not intended to limit the present invention to negative-pressure wound therapy devices only.
New and useful systems, apparatuses, and methods for maintaining negative-pressure in low and high leak conditions in a negative-pressure therapy environment are disclosed herein. Illustrative embodiments are also provided to enable a person skilled in the art to make and use the claimed subject matter.
The reduced pressure provided by a reduced pressure treatment system to a tissue site such as, for example, an incision or a wound may need to be properly controlled to increase the effectiveness of the reduced pressure treatment. The reduced pressure treatment system may include a pump for providing reduced pressure, a wound dressing disposed adjacent the wound, and a drape that covers both to provide a sealed environment for providing the reduced pressure treatment from the pump to the sealed environment. Leaks and blockages may occur in the components of the reduced pressure treatment system such as, for example, leaks between the drape and the tissue site, that may need to be detected in order to adjust the pressure provided by the pump to maintain effective treatment.
The type of method used for controlling reduced pressure treatment systems, i.e., the wound site pressure control band, may vary depending on the magnitude of the pressure leaks or blockages and/or the rate of change of the pressure leaks or blockages. Consequently, the wound site pressure control band best suited for a high leak rate may be different from the wound site pressure control band best suited for a low leak rate. For example, a system controller and control methods are described herein that include both a narrow hysteresis control band and a wide hysteresis control band and an algorithm for switching between the two based on the level of leakage of components in the negative-pressure treatment system. The system controller and control methods may select the wide hysteresis control band for high leakage conditions to conserve battery power and reduce noise from the pump. More specifically, the system controller may include a bang-bang controller and the bang-bang controller might operate more frequently to maintain the narrow hysteresis control band in a high leakage condition which would reduce battery power and expose the patient to frequent humming of the pump, while the electric motor controller might operate less frequently to maintain the wide hysteresis control band which would conserve battery power and be less irritating to the patient because it would not need to be on as frequently.
In one embodiment, a system comprises a negative-pressure source including a pump and an electric motor for maintaining negative-pressure at a wound site and a pressure sensor for sensing a wound site pressure (WP). The system may further comprise a system controller coupled to the first pressure sensor and the electric motor. The system controller may maintain the wound site pressure (WP) within a hysteresis band by the application of power to the electric motor from a battery power source, based upon, at least in part, a flow rate (FR) of fluid between the pump and the wound site as determined by the system controller. The hysteresis band may include a maximum wound site pressure (WPMax) and a minimum wound site pressure (WPMin).
In another example embodiment, a system for stimulating healing of tissue at a wound site comprises a manifold configured to be positioned at a wound site and adapted to be covered by a drape to form a seal around the wound site for maintaining negative-pressure at the wound site. The system may further include a negative-pressure source and the negative-pressure source may include a pump and an electric motor for driving the pump in response to an application of power from a power source, and the pump may be adapted to generate a pump pressure (PP) and may be adapted to be fluidly coupled to the porous pad for the application of negative-pressure to the wound site. The system may further include a first pressure sensor and the pressure sensor may have an input for sensing a wound site pressure (WP) and an output for providing a wound site pressure signal indicative of the wound site pressure (WP). The system may further include a system controller electrically coupled to the output of the first pressure sensor and the electric motor to control the wound site pressure (WP) at the wound site, the system controller may further include a bang-bang controller and the bang-bang controller may be configured to compare the wound site pressure (WP) to a hysteresis control band and may maintain the wound site pressure (WP) within the hysteresis control band. The hysteresis control band may further include a maximum wound site pressure (WPMax) and a minimum wound site pressure (WPMin), and the maximum wound site pressure (WPMax) and a minimum wound site pressure (WPMin) may be based upon, at least in part, a flow rate (FR) of fluid between the pump and the porous pad, which may be determined by the system controller.
One or more of the following features may be included. The system may also be a portable system powered by a primary cell battery and the primary cell may be a non-rechargeable lithium battery; alternatively the portable system may be powered by a secondary cell battery and the secondary cell may be a rechargeable lithium-ion battery. The pump may be a diaphragm pump and the electric motor may be a Direct Current (DC) motor and the power applied to the DC motor may be varied by varying a voltage applied to the DC motor or a current drawn by the DC motor. The system controller may be configured to determine a flow rate (FR) by a time rate of change of the voltage applied to or the current drawn by the DC motor, and further configured to select a narrow hysteresis control band when the flow rate (FR) is less than a first target flow rate (TFR1), indicating a low-leak condition in the system, and a wide hysteresis control band when the flow rate (FR) is greater than a second target flow rate (TFR2), indicating a high-leak condition in the system. The first target flow rate (TFR1) may be less than the second target flow rate (TFR2) or substantially equal to the second target flow rate (TFR2). The system controller may be configured to determine the battery charge level (BCL) and further configured to select a wide hysteresis control band if the battery charge level (BCL) is less than a first target battery charge level (TCL1), indicating a low battery charge level in the system, and a narrow hysteresis control band if the battery charge level (BCL) is greater than a second target battery charge level (TCL2), indicating a high battery charge level in the system. The first target battery charge level (TCL1) may be less than the second target battery charge level (TCL2) or substantially equal to the second target battery charge level (TCL2). The bang-bang controller may reduce negative-pressure at the wound site by reducing the power applied to the DC motor when the wound site pressure (WP) is greater than the maximum wound site pressure (WPMax) and may increase negative-pressure at the wound site by increasing the power applied to the DC motor when the wound site pressure (WP) is less than the minimum wound site pressure (WPMin). The system may also include a second pressure sensor and the pressure sensor may have an input for sensing a pump pressure (PP) and an output providing a pump pressure signal to the system controller indicative of the pump pressure (PP).
Objectives, advantages, and a preferred mode of making and using the claimed subject matter may be understood best by reference to the accompanying drawings in conjunction with the following detailed description of illustrative embodiments.
The following description of example embodiments provides information that enables a person skilled in the art to make and use the subject matter set forth in the appended claims, but may omit certain details already well-known in the art. The following detailed description is, therefore, to be taken as illustrative and not limiting.
The example embodiments may also be described herein with reference to spatial relationships between various elements or to the spatial orientation of various elements depicted in the attached drawings. In general, such relationships or orientation assume a frame of reference consistent with or relative to a patient in a position to receive treatment. However, as should be recognized by those skilled in the art, this frame of reference is merely a descriptive expedient rather than a strict prescription.
The reduced pressure applied to the tissue site 105 may be provided by a reduced pressure source 110. Reduced pressure source 110 may be any type of manually, mechanically, or electrically operated pump. Non-limiting examples of reduced pressure source 110 include devices that are driven by stored energy, and which are capable of producing a reduced pressure. Examples of these stored energy, reduced pressure sources include, without limitation, pumps driven by primary and secondary cells, piezoelectric energy, spring energy, solar energy, kinetic energy, energy stored in capacitors, combustion, and energy developed by Sterling or similar cycles. Still other devices and processes that may be used or included in reduced pressure source 110 include syringes, lead screws, ratchets, clockwork-driven devices, pendulum-driven devices, manual generators, osmotic processes, thermal heating processes, and processes in which vacuum pressures are generated by condensation. In another embodiment, reduced pressure source 110 may include a pressure pump 112 wherein the pressure pump 112 provides negative or reduced pressure, i.e., a pump pressure (PP), to the tissue site 105 that may be driven by a DC motor 114 electrically coupled to a system controller 170 which is also a component of the reduced-pressure therapy system 100, also referred to as a system controller. Preferably, the pressure pump 112 uses low amounts of power and is capable of operating for an extended period of time on a single charge of a battery (not shown) such as, for example, a diaphragm pump 112. The electric motor 114 may be a direct-current motor powered by a DC power supply such as, for example, the battery.
In some embodiments, the provision of negative-pressure wound therapy over a therapeutic life cycle, which may be 7-day (168-hour) or more therapeutic life cycle, may be performed by a small portable therapy device 100 powered by a primary cell battery, which may be a non-rechargeable lithium battery. The small portable therapy device 100 may further be disposable and may use a primary non-rechargeable battery to avoid adding cost to a disposable unit or inconveniencing the user by requiring the battery to be periodically charge the battery during the therapeutic life cycle. The small portable therapy device 100 may also be powered by a plurality of batteries. For example, the small portable therapy device 100 may be powered by 3 AA sized batteries. Alternatively the small portable therapy device 100 may be powered by a secondary cell battery, which may be a rechargeable lithium-ion battery pack or a rechargeable lithium polymer battery pack, wherein the period of time between subsequent recharges of the battery may be increased as a result of the system and methods disclosed herein. The small portable device may further be configured with integrated inductive coil, which may facilitate wireless charging of the secondary cell battery of the small portable therapy device 100 while being worn, during periods of patient rest, or both.
In one example embodiment, the reduced pressure source 110 comprises a DC motor 114 powered by the battery, i.e., the applied power. The applied power may be varied to control the speed of the DC motor 114 by varying either the current or the voltage applied to the DC motor 114, i.e., the “applied voltage” (VA). The applied voltage (VA) may be varied, for example, by modulating the voltage with a square wave and varying the duty cycle of the square wave to control the speed of the DC motor 114. The reduced pressure source 110 also comprises a pressure pump 112 that provides a reduced pressure or vacuum to the tissue site 105. Consequently, the pressure pump 112 represents the load on the DC motor 114 so that when the therapy requires that the reduced pressure at the tissue site 105 needs to be increased, the applied voltage (VA) provided to the DC motor 114 is increased to achieve the targeted reduced pressure at the tissue site 105. One skilled in the art knows that the DC motor 114 will not run or turn the pump until the applied voltage (VA) is sufficient to overcome the inertia or load of the pressure pump 112, which in this case may be a diaphragm pump 112.
Referring more specifically to
The specific stall voltage for a specific DC motor 114 used to drive a diaphragm pump 112 can typically be determined by one skilled in the art from the specifications available for the DC motor 114. The diaphragm pump and DC motor 114 may be an integrated device such as, for example, a Thomas Model No. 30130002 series 4.5V diaphragm pump 112 for which such information is readily available. (Thomas; thomas.de@gardnerdenver.com) Referring again to
Data from pump specifications is typically limited to the relation of maximum flow to vacuum pressure at maximum pump voltage (e.g., 4.5V for Thomas pump identified above). Positive pressures are specified in mbar units (mmHg of positive pressure=0.7500616827042*mbars) and vacuum pressures are specified in terms of percent vacuum. For example, if 100% maximum vacuum is specified at 760 mmHg, 40% maximum vacuum would be equal to 304 mmHg of vacuum (=0.4*760 mmHg). In this example, the 304 mmHg of vacuum pressure would be the theoretical maximum vacuum pressure that we could attain if the pump was run at 4.5V and allowed to run until it the DC motor 114 stalls. The graph 301 in
The equation for calculating the stall voltage for this particular pump is as follows: Stall Voltage=1.638V+(0.006515V/mmHg*XmmHg), where X is the current vacuum pressure. Therefore, at 50 mmHg of vacuum, the stall voltage equals 1.96V (1.638+(0.006515*50)); at 125 mmHg of vacuum, the stall voltage equals 2.45V (1.638+(0.006515*125)) as indicated by the dashed lines 304, 305; and at 175 mmHg of vacuum, the stall voltage equals 2.78V (1.638+(0.006515*175)) as indicated by the dashed lines 306, 307. Again, the higher the vacuum pressure, the higher the applied voltage that is needed to start the pump. Otherwise, the pump stalls and will not move until the necessary stall will voltage is applied. When the pump stalls, the DC motor 114 simply overheats which can damage the DC motor 114 and reduce battery life.
In some embodiments, the diaphragm pump 112 may be designed to pump liquids, slurries, sludge or a combination thereof. There are many advantages to using a diaphragm pump 112 in a negative-pressure wound therapy device. For example, diaphragm pumps may be designed to handle liquids with different viscosities and even liquids that contain a considerable amount of solid material. Diaphragm pumps may further be manufactured from almost any material which makes them suitable for medical applications and are self-priming. However, despite the many advantages of using a diaphragm pump in a negative-pressure wound therapy device they do have some limitations in terms of their operating efficiency. For example, like many electrical devices, particularly many types of electric motor, diaphragm pumps are subject to an inrush current, which may be significantly higher than the steady state value. This inrush current or switch-on surge current is the maximum, instantaneous current drawn by an electrical device when it if first turned on, and may persist at this level for a couple of cycles in the case of a motor before dropping back to the steady state value. For example, in the case of the diaphragm pump 112 the current drawn may drop by 60% or more from its initial peak inrush value to its steady state value. Furthermore, the physical components of the pneumatic section of the diaphragm pump 112 may also have an initial static friction associated with them that has to be overcome at startup. For at least these reasons the diaphragm pump 112 may need to complete a number of cycles before it starts to effectively perform.
Referring more specifically to
The additional energy used during the first 35 ms=0.023 J
Or 438 mA×0.5×3V×35 ms (1)
The approximate energy used in the first 35 ms=0.052 J
Or 0.23 J+277 mA×3V×35 ms (2)
The energy used in a steady state one second period32 0.831 J
Or 277 mA×3V×1 S (3)
The total energy used during a one second pulse=0.854 J
Or 0.831 J+0.023 J (4)
The total energy used during a half second pulse=0.438 J
Or 0.415 J+0.023 J (5)
Referring again to (4) and (5) it can be seen that the additional energy used during the first 35 ms (0.023 J) as a result of the inrush current may become increasingly significant as the pulse duration is and fully OFF for 9 seconds, and repeat, to maintain an average target pressure of 125 mmHg at the wound site, wherein the total energy used during the one second pulse may be 0.854 J. In this instance the pressure at the wound site may cycle within a relatively wide tolerance band. Alternately the system controller 170 may be configured to maintain the average target pressure by turning the pump 112 fully ON for 100 ms in every 1 second period, wherein the total energy used during a comparable 10 second period would be 1.060 J or 0.831 J+0.023 J×10. In this instance the pressure at the wound site may cycle within a relatively small tolerance band but a significant percentage (21%) of the power feed will be allocated to these start-up inefficiencies rather than maintaining the average target pressure and this will adversely affect the battery capacity required to achieve the therapeutic life cycle. As an illustrative example, in testing a simple system that used a pressure switch and a simple electronic circuit to control a pump showed an increase of battery life of 16% when switching from a narrow hysteresis control band (2 mmHg span) to a wide hysteresis control band (10 mmHg span).
We will further see in the bang-bang control system disclosed below that a bang-bang control system with narrow limits will require a proportionally greater number of starts than a bang-bang control system with wider limits and will therefore incur more of the inefficiencies associated with start-ups while maintaining a target pressure (TP). The controller system may utilize this characteristic, for example, in some instances it may be preferable to compete the therapeutic life cycle with a relatively wide tolerance band rather than attempt to maintain a narrow tolerance band and fail to do so because the batteries have insufficient capacity to do so. In some instances the system may also be configured to returned to the narrow hysteresis control band once it has determined that the batteries have been recharged/replaced or the leak is have been addressed.
Referring back to
In one embodiment, manifold 120 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam such as GranuFoam manufactured by Kinetic Concepts, Inc. of San Antonio, Tex. If an open-cell foam is used, the porosity may vary, but is preferably about 400 to 600 microns. The flow channels allow fluid communication throughout the portion of manifold 120 having open cells. The cells and flow channels may be uniform in shape and size, or may include patterned or random variations in shape and size. Variations in shape and size of the cells of manifold result in variations in the flow channels, and such characteristics may be used to alter the flow characteristics of fluid through manifold 120. The manifold 120 may further include portions that include “closed cells.” These closed-cells portions of manifold 120 contain a plurality of cells, the majority of which are not fluidly connected to adjacent cells. Closed-cell portions may be selectively disposed in manifold 120 to prevent transmission of fluids through perimeter surfaces of manifold 120.
Manifold 120 may also be constructed from bioresorbable materials that do not have to be removed from a patient's body following use of reduced pressure therapy system 100. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones. Manifold 120 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with manifold 120 to promote cell-growth. A scaffold is a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials. In one example, the scaffold material has a high void-friction (i.e., a high content of air).
The dressing 115 may also include sealing member 125 also referred to as a drape or cover. Manifold 120 may be secured to tissue site 105 using sealing member 125. Sealing member 125 may be a cover that is used to secure manifold 120 at tissue site 105. While sealing member 125 may be impermeable or semi-permeable, in one example sealing member 125 is capable of maintaining a reduced pressure at tissue site 105 after installation of the sealing member 125 over manifold 120. Sealing member 125 may be a flexible drape or film made from a silicone based compound, acrylic, hydrogel or hydrogel-foaming material, or any other biocompatible material that includes the impermeability or permeability characteristics desired for tissue site 105. Sealing member 125 may be formed of a hydrophobic material to prevent moisture absorption by the sealing member 125. In one embodiment, sealing member 125 is configured to provide a sealed connection with the tissue surrounding manifold 120 and tissue site 105. The sealed connection may be provided by an adhesive (not shown) positioned along a perimeter of sealing member 125 or on any portion of sealing member 125 to secure sealing member 125 to the manifold 120 or the undamaged epidermis peripheral to a tissue site, i.e., the peritissue. The adhesive may be pre-positioned on sealing member 125 or may be sprayed or otherwise applied to sealing member 125 immediately prior to installing sealing member 125.
In general, components of the therapy system 100 may be coupled directly or indirectly. Components may be fluidly coupled to each other to provide a path for transferring fluids (i.e., liquid and/or gas) between the components. In some embodiments, for example, components may be fluidly coupled through a tube. A “tube,” as used herein, broadly refers to a tube, pipe, hose, conduit, or other structure with one or more lumina adapted to convey a fluid between two ends. Typically, a tube is an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary. In some embodiments, components may additionally or alternatively be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts
The reduced pressure generated by reduced pressure source 110 may be applied to tissue site 105 through source tube 130 and delivery tube 135. Source tube 130 and delivery tube 135 may be any tube through which a gas, liquid, gel, or other fluid may flow. For example, exudate from tissue site 105 may flow through delivery tube 135. In
Source tube 130 and delivery tube 135 may be made from any material. Source tube 130 and delivery tube 135 may be either flexible or inflexible. Also, source tube 130 and delivery tube 135 may include one or more paths or lumens through which fluid may flow. For example, delivery tube 135 may include two lumens. In this example, one lumen may be used for the passage of exudate from tissue site 105 to canister 140. The other lumen may be used to deliver fluids, such as air, antibacterial agents, antiviral agents, cell-growth promotion agents, irrigation fluids, or other chemically active agents, to tissue site 105. The fluid source from which these fluids originate is not shown in
In one embodiment, delivery tube 135 is coupled to manifold 120 via connection member 145. Connection member 145 permits the passage of fluid from manifold 120 to delivery tube 135, and vice versa. For example, exudates collected from tissue site 105 using manifold 120 may enter delivery tube 135 via connection member 145. In another embodiment, reduced pressure therapy system 100 does not include connection member 145. In this embodiment, delivery tube 135 may be inserted directly into sealing member 125 or manifold 120 such that an end of delivery tube 135 is adjacent to or in contact with manifold 120.
Liquid, such as exudate, from tissue site 105 may flow through delivery tube 135 into canister 140. Canister 140 may be any device or cavity capable of containing a fluid, such as gases and liquids, as well as fluids that contain solids. For example, canister 140 may contain exudates from tissue site 105. Source tube 130 and delivery tube 135 may be directly connected to canister 140, or may be coupled to canister 140 via a connector, such as connector 150, as indicated by arrow 151. The canister 140 may be a flexible or rigid canister, a bag, or pouch fluidly connected to manifold 120 by delivery tube 135. Canister 140 may be a separate canister or may be operably combined with reduced pressure source 110 to collect exudate and fluids.
Reduced pressure therapy system 100 may further comprise a first pressure sensor 155 electrically coupled to the system controller 170. First pressure sensor 155 detects an actual reduced pressure at or proximate the tissue site 105, i.e., the tissue site pressure or wound site pressure (WP). The reference to the word “wound” as part of the term wound site pressure (WP) is exemplary only and does not limit the term or description herein as applying to the measurement of pressure at other types of tissue sites such as, for example, incisions or subcutaneous cavities. In one non-limiting example, first pressure sensor 155 is a silicon piezo-resistive gauge pressure sensor. First pressure sensor 155 may be configured to detect the wound site pressure (WP) via a control tube 160 fluidly coupled to the connection member 145 or via one of the lumens of the delivery to 135 as described above through the connector 150. Control tube 160 is any tube through which a gas may flow. Control tube 160 may be made from any material. Control tube 160 may be either flexible or inflexible. Also, control tube 160 may include one or more paths or lumens through which fluid may flow.
Reduced pressure therapy system 100 may further comprise a second pressure sensor 156 electrically coupled to the system controller 170. Second pressure sensor 156 detects a reduced pressure at or downstream from the canister 140 indicated by arrows 157 and 158, respectively, i.e., the pump pressure (PP). In one non-limiting example, second pressure sensor 156 is a silicon piezo-resistive gauge pressure sensor. The second pressure sensor 156 may be fluidly coupled directly to the canister 144 or the source tube 130, or indirectly via a control tube (not shown) as indicated by the arrows 157 and 158, to detect the pump pressure (PP). The second pressure sensor 156 may also be fluidly coupled to the canister 144 through the connector 150.
In
In another embodiment, delivery tube 135 and control tube 160 are each lumens in a single multi-lumen tube. Source tube 130 and control tube 160 may also each be lumens in a single multi-lumen tube. In the example in which reduced pressure source 110 is coupled to manifold 120 using only delivery tube 135, a single multi-lumen tube may be used to couple both reduced pressure source 110 and first pressure sensor 155 to manifold 120. Turning to
Multi-lumen tube 190 includes two lumens. Specifically, multi-lumen tube 190 includes lumens 192 and 194. Although multi-lumen tube 190 includes two lumens 192 and 194, multi-lumen tube may have any number of lumens, such as three, four, or ten. In one embodiment, one of lumens 192 and 194, such as lumen 192, is a delivery tube or source tube, such as delivery tube 135 and source tube 130 in
In some embodiments, pressure sensors 155 and 156 may be located anywhere on or within the reduced pressure therapy system 100, for example, they may be wireless sensors. Referring back to
Reduced pressure therapy system 100 may also include control tube valve 165. Control tube valve 165 may be coupled to control tube 160 as indicated by arrow 166 or indirectly coupled to the source tube 134 or the canister 140 as indicated by arrow 168. Control tube valve 165 may be any valve capable of relieving the reduced pressure in control tube 160. Non-limiting examples of control tube valve 165 include a pneumatic solenoid valve, a proportional valve, or a mechanical valve. In one example, control tube valve 165 may be manually controlled by a caregiver. In another example, control tube valve 165 may be controlled by the system controller 170. In one embodiment, control tube valve 165 may be opened to relieve the reduced pressure in control tube 160 or the source tube 130 when a blockage is detected in either one. Such a blockage may occur, for example, when exudate or other fluid from tissue site 105 clogs control tube 160 or the source tube 130. By relieving the reduced pressure in control tube 160 or the source tube 130 via control tube valve 165, the blockage may be cleared from either one.
In operation, the manifold 120 may be placed within, over, on, or otherwise proximate to a tissue site. The sealing member 125 may be placed over the manifold 120 and sealed to tissue near the tissue site 105. For example, the sealing member 125 may be sealed to undamaged epidermis peripheral to a tissue site, i.e., the peritissue. Thus, the dressing 115 can provide a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, and the reduced pressure source 110 can reduce the pressure in the sealed therapeutic environment. Reduced pressure applied across the tissue site through the manifold 120 in the sealed therapeutic environment can induce macrostrain and microstrain in the tissue site, as well as remove exudates and other fluids from the tissue site, which can be collected in the canister 140 and disposed of properly.
The fluid mechanics of using a reduced-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative-pressure therapy are generally well-known to those skilled in the art, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” negative-pressure, for example.
In general, exudates and other fluids flow toward lower pressure along a fluid path. Thus, the term “downstream” typically implies something in a fluid path relatively closer to a reduced-pressure source, and conversely, the term “upstream” implies something relatively further away from a negative-pressure source. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference. This orientation is generally presumed for purposes of describing various features and components of reduced-pressure therapy systems herein. However, the fluid path may also be reversed in some applications (such as by substituting a positive-pressure source for a reduced-pressure source) and this descriptive convention should not be construed as a limiting convention.
The term “tissue site” in this context broadly refers to a wound or defect located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example. The term “tissue site” may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative-pressure may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
The term “negative or reduced pressure” generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment provided by the dressing 102. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in negative-pressure typically refer to a decrease in absolute pressure, while decreases in negative-pressure typically refer to an increase in absolute pressure.
A negative-pressure source, such as the reduced pressure source 110, may be a reservoir of air at a reduced pressure, or may be a manual or electrically-powered device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro-pump, for example. A negative-pressure source may be housed within or used in conjunction with other components, such as processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate negative-pressure therapy. For example, the reduced pressure source 110 and the system controller 170 may be housed within a therapy control unit. While the amount and nature of negative-pressure applied to a tissue site may vary according to therapeutic requirements, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between −5 mm Hg (−667 Pa) and −500 mm Hg (−66.7 kPa). Common therapeutic ranges are between −75 mm Hg (−9.9 kPa) and −300 mm Hg (−39.9 kPa).
As indicated above, the applied voltage (VA) provided to the DC motor 114 is used to control the pump pressure (PP) and ultimately achieve the desired or targeted pressure at the tissue site 105. Correspondingly, the applied voltage (VA) provides an indication of the pump pressure (PP) and may be monitored by the system controller 170 which in turn may determine the time rate of change of the applied voltage (VA) that necessarily corresponds to the time rate of change of the pump pressure (PP). The controller 170 may use this computation for determining the flow rate of air between the reduced pressure source 110 and tissue site 105, i.e., the flow rate (FR). In another embodiment, the reduced pressure therapy system 100 may further comprise a sensing device (not shown) that directly measures the flow rate (FR) such as, for example, a flow-meter or a differential processor for computing the time rate of change in the difference between the wound site pressure (WP) and the pump pressure (PP). The flow rate (FR) may be measured, for example, as cubic centimeters of air per minute (cc/min), between the reduced pressure source 110 and the tissue site 105. The flow rate (FR) provides some indication of the extent to which the dressing 115 or other components of the negative-pressure system 100 might be leaking to reduce the pressure at the tissue site 105 below the desired pressure targeted for therapy. For example, a high flow rate (FR) might indicate that the dressing 115 or other components of the therapy system 100 are considered to be in a “high leakage condition,” while a lower flow rate (FR) might indicate that the dressing 115 or other components of the therapy system 100 are considered to be in a more efficient “low leakage condition” requiring less battery power for driving the DC motor 114 to continue running in order to offset the lower leakage.
The controller 170 may be an integrated or separate component of the reduced-pressure treatment system 100. Controller 170 may be any device capable of processing data, such as data from first pressure sensor 155 and/or the second pressure sensor 156. Controller 170 may also control the operation of one or more components of reduced pressure therapy system 100, such as reduced pressure source 110, DC motor 114, control tube valve 165, pressure sensors 155 and 156, and an indicator 172. The controller 170 may control and receive data from other components (not shown) of the reduced pressure source 110 including the pressure pump 112 and the DC motor 114. In one embodiment, controller 170 receives and processes data, such as the wound site pressure (WP) from the first pressure sensor 155, the pump pressure (PP) from the second pressure sensor 156, and the flow rate (FR) from monitoring the applied voltage (VA) to the DC motor 114 as described above. The controller 170 may also control the operation of one or more components of reduced pressure therapy system 100 to manage the wound site pressure (WP) at tissue site 105. In one embodiment, controller 170 may including an input for receiving a desired target pressure (TP) set by a clinician or other user and may be program for processing data relating to the setting and inputting of the target pressure (TP) to be applied to the tissue site 105.
In one example embodiment, the target pressure (TP) may be a fixed pressure value determined by a user/caregiver as the reduced pressure target desired for therapy at the tissue site 105 and then provided as input to the system controller 170. The user may be a nurse or a doctor or other approved clinician who prescribes the desired reduced pressure to which the tissue site 105 should be applied. The desired tissue site pressure will vary from tissue site to tissue site, but will generally be chosen based on the type of tissue making up the tissue site, the type of injury or wound (if any), the medical condition of the patient, and the preference of the attending physician. After selecting the desired target pressure (TP), the reduced pressure source 110 is controlled to achieve the target pressure (TP) desired for application to the tissue site 105.
Referring more specifically to
It should be understood that the increase of the wound site pressure (WP) at the tissue site 105 from the local ambient pressure to the target pressure (TP) is not instantaneous, but rather limited depending on the type of therapy equipment and the dressing. For example, the reduced pressure source 110 and the dressing 115 may have an initial rise time as indicated by the dashed line 407 that may vary depending on the type of dressing and therapy equipment being used. For example, the initial rise time for one therapy system may be in the range between about 20-30 mmHg/second or, more specifically, equal to about 25 mmHg/second, and in the range between about 5-10 mmHg/second for another therapy system. When the therapy system is operating in the intermittent mode, the repeating rise time 405 may be a value substantially equal to the initial rise time 407.
In some embodiments, the target pressure (TP) may also be a variable target pressure (VTP) controlled or determined by controller 170 that varies in a dynamic pressure mode. For example, the variable target pressure (VTP) may vary between a maximum and minimum pressure value that may be set as an input by a user as the range of reduced pressures desired for therapy at the tissue site 105. The variable target pressure (VTP) may also be processed and controlled by controller 170 that varies the target pressure (TP) according to a predetermined waveform such as, for example, a sine waveform or a saw-tooth waveform or a triangular waveform, that may be set as an input by a user as the predetermined or time-varying reduced pressures desired for therapy at the tissue site 105. For example, the variable target pressure (VTP) may be a reduced pressure that provides an effective treatment by applying reduced pressure to tissue site 105 in the form of a triangular waveform varying between 50-125 mmHg with a rise time set at +25 mmHg/min and a descent time set at −25 mmHg/min. In another embodiment of a reduced-pressure therapy system 100, the variable target pressure (VTP) may be a reduced pressure that applies reduced pressure to tissue site 105 in the form of a triangular waveform varying between 25-125 mmHg with a rise time set at a rate of +30 mmHg/min and a descent time set at −30 mmHg/min. Again, the type of system and tissue site determines the type of reduced pressure therapy to be used.
After selecting the target pressure (TP), the reduced pressure source 104 is operated to achieve the desired pressure at the tissue site 105 by controlling the pump pressure (PP). In many cases, the reduced pressure source 110 to be operated at a higher pump pressure (PP) than that of the target pressure (TP) due to pressure losses between the reduced pressure source 110 and the tissue site 105. Moreover, the head pressure of exudates and other fluids within the conduits may result in a reduction of vacuum pressure at the tissue site 105. The height of the canister 140 above the tissue site 105 may determine the amount of head pressure imposed on the tissue site 105 by fluid in the conduits. For exudates and fluids with a density similar to water, the head pressure imposed by one foot of fluid is almost 25 mmHg. Some fluids withdrawn from the tissue site 105 may be even heavier or more viscous than water, and therefore have a more pronounced effect on pressure losses at the tissue site 105.
Referring to
The controller 170 may also be programmed and controlled by a user to maintain the target pressure (TP) within an acceptable range of pressures. For example, if the target pressure (TP) is set at 125 mmHg as the desired therapeutic pressure for the tissue site 105, a user may desire that the wound site pressure (WP) varies by no more than ±10 mmHg from the desired target pressure (TP) so that the wound site pressure (WP) is controlled between a minimum wound site pressure value (WPmin) of 115 mmHg and a maximum wound site pressure value (WPmax) of 135 mmHg, i.e., a differential wound site pressure range (δWP) of about 20 mmHg. Therefore, assuming for this example that there is a head pressure approximately 50 mmHg as described above, the pump pressure (PP) must also be variable by ±10 mmHg from the target pump pressure (TPP) so that the pump pressure (PP) may be varied in a range extending from the minimum pump pressure value (PPmin) of approximately 165 mmHg to the maximum pump pressure value (PPmax) of approximately 185 mmHg, i.e., a differential pump pressure (δTTP) of about 20 mmHg. Controlling the pump pressure (PP) to stay within this range indirectly maintains the wound site pressure (WP) within a range extending from the minimum wound site pressure value (WPmin) of approximately 115 mmHg to the maximum wound site pressure value (WPmax) of approximately 135 mm.
Referring to
The controller 170 may also comprise a bang-bang controller (not shown) which is also referred to as an on-off controller, or a hysteresis controller. The bang-bang controller is a feedback controller that switches abruptly between two states, e.g., between on and off. Essentially, the bang-bang controller may apply an all-or-nothing form of control. A bang-bang controller may be used to generate the pressure variations described generally above in conjunction with
In some embodiments, the bang-bang voltage (VON) continues to be applied until the wound site pressure (WP) reaches the maximum wound site pressure (WPmax). When the maximum wound site pressure (WPmax) is reached or exceeded, the pressure pump 112 is turned off at an off time (toff) so that no pump pressure (PP) is applied allowing the residual pressure in the reduced pressure therapy system 100 to decrease as a result of the leakage in the system. The pressure pump 112 remains off until the wound site pressure (WP) is again less than or equal to the minimum wound site pressure value (WPmin). In some embodiments, the residual pressure may also be reduced more quickly by opening a relief valve (not shown) that vents air pressure from the system.
In some embodiments, the bang-bang voltage (VON) to be applied until the pump pressure (PP) reaches the maximum pump pressure value (PPmax) or the wound site pressure (WP) reaches the maximum wound site pressure value (WPmax), whichever occurs first. When either one of these maximum values is reached or exceeded, the pressure pump 112 is turned off at an off time (toff) so that no pump pressure (PP) is applied allowing the residual pressure in the reduced pressure therapy system 100 to decrease as a result of the leakage in the system. The pressure pump 112 remains off until the wound site pressure (WP) is again less than or equal to the minimum wound site pressure value (WPmin) or the pump pressure (PP) is less than or equal to the minimum pump pressure value (PPmin), whichever occurs first. In some embodiments, the residual pressure may also be reduced more quickly by opening the relief valve.
The bang-bang controller switches between these two states wherein the pressure pump 112 is turned on when the wound site pressure or the pump pressure drops too low in a descending mode and turns the pressure pump 112 off when the wound site pressure or pump pressure rises too high in an ascending mode. The bang-bang controller allows the wound site pressure (WP) to oscillate proximate the target pressure (TP) of 125 mmHg as contained between the two limits of a hysteresis control band that a user programs into the system controller 170, e.g., the minimum wound site pressure value (WPmin) of 115 mmHg and the maximum wound site pressure value (WPmax) of 135 mmHg. The wound site pressure (WP) is not pulled back within the hysteresis control band or wound site pressure range (δWP) of 20 mmHg unless the wound site pressure (WP) exceeds either one of these limits. The bang-bang controller maintains the wound site pressure (WP) substantially within this range because the bang-bang controller does not need to overcompensate for leakage in a low-leakage environment. The controller 170 may further include an input for a user/caregiver to set one or more limits of the hysteresis control band and there may be a plurality of hysteresis control bands. The system may further include an output for the user/caregiver and the output may be a hysteresis control band status indicator, for instance the hysteresis control band status indicator may indicate whether the hysteresis control band is currently set to narrow or wide as discussed herein.
In some embodiments, the system controller 170 may also include a Proportional Integral Derivative (PID) controller (not shown) that provides a control loop feedback mechanism that calculates an error value as the difference between a measured process variable and a desired set point or target, in this case the wound site pressure (WP) and the corresponding target pressure (TP) at the tissue site 105, respectively. PID controllers are well-known by those skilled in the art as providing proportionality information, historical information, and time rate of change information to maintain the wound site pressure (WP) close to the target pressure (TP). The PID summation is used to adjust the process, in this case the reduced pressure therapy process, by a control element such as the power or voltage supplied to a DC motor 114, i.e. the applied voltage (VA), which is directly related to the pump pressure (PP) as described above. The applied voltage (VA) may be varied as described above by adjusting the Pulse-Width Modulation (PWM) to achieve the desired pump pressure (PP) necessary to compensate for the leakage of the dressing 115 and/or the pressure head referred to above. The response of the PID controller is dependent on the responsiveness of the PID controller to an error, the degree to which the PID controller overshoots the set-point, e.g., the target pressure (TP), and the degree of system oscillation, e.g., the degree of oscillation of the wound site pressure (WP) within the acceptable range described above. Although a preferred embodiment of the PID controller is a digital controller, the PID controller may also be an analog controller or a simple RC circuit. The analog or digital PID controller may be implemented in hardware components or software as part of a program logic controller well-known in the art.
After the first pressure sensor 155 measures the wound site pressure (WP), the PID controller adjusts the pump pressure (PP) by supplying the applied voltage (VA) necessary for adjusting the wound site pressure (WP) back to the target pressure (TP), i.e., the pump pressure correction (δPP). The pump pressure correction (δPP) is the additional pressure needed to maintain the wound site pressure (WP) at the desired target pressure (TP), e.g., 125 mmHg, and may be calculated every few seconds. Consequently, the PID control varies the applied voltage (VA) to the DC motor 114 to achieve a pump pressure (PP) between a minimum pump pressure value (PPmin) and a maximum pump pressure value (PPmax) which maintains the wound site pressure (WP) proximate the target wound site pressure (TP).
Referring more specifically to
Unlike the bang-bang controller, the PID controller does not switch the pressure pump 112 on and off, but rather continuously controls the application of the pump pressure (PP) between the maximum and minimum pressure values, (PPmax) and (PPmin), to maintain the wound site pressure (WP) at a relatively constant level, e.g., at a target pressure (TP) all of 125 mmHg as shown by the dashed line, rather than allowing it to vary between a maximum and minimum pressure value, (WPmax) and (WPmin) as shown with the bang-bang controller. Therefore, the extent to which the pump pressure (PP) drops towards the minimum pump pressure value (PPmin), the more that the PID controller increases the applied voltage (VA) being provided to the DC motor 114. Correspondingly, the further the wound site pressure (WP) varies from the target pressure (TP), the more the PID controller responds by adjusting the applied voltage (VA) being provided to the DC motor 114. The action taken to increase or decrease the applied voltage (VA) is proportional to the degree that the wound site pressure (WP) provided by the reduced pressure system diverges from the target wound site pressure (TP). The PID controller continuously operates in order to keep the wound site pressure (WP) as close to the target wound site pressure (TP) as possible, especially for high leakage rates (LR). Consequently, the PID controller causes the reduced pressure therapy system 100 to run smoother than the bang-bang controller as shown when comparing the wound site pressure (WP) variations of
When the flow rate (FR) is small enough to indicate a low leakage condition, e.g., when the pump pressure (PP) or the wound site pressure (WP) is decreasing at a very slow rate toward their respective minimum pressure values, i.e., (PPmin) or (WPmin), the bang-bang controller may provide a sufficiently smooth wound site pressure (WP) during treatment while conserving battery power and reducing noise by virtue of the pressure pump 112 being intermittently turned off during the same treatment period. For example, the DC motor 114 and pressure pump 112 are turned off for a significant percentage of time during the one minute period shown in
Thus, the system controller 170 may be programmed to use the bang-bang controller in conjunction with the PID controller operating as described above to enable or disable the PID controller depending on a specific switching condition relating to the amount of air leakage created by the dressing 115 or other components of the reduced pressure therapy system 100 that affect the flow rate (FR). Using such a hybrid controller would be preferable to utilizing only a PID controller which runs continuously during the continuous control mode as described above (or the enabled portions of an intermittent control mode as described above) to more tightly maintain the wound site pressure (WP) at the target wound site pressure (TP), but may continually generate noise and more rapidly drain the battery driving the DC motor 114. The hybrid controller may engage the bang-bang controller so that the DC motor 114 is turned on and off to conserve battery power and reduce noise generated by the pressure pump 112 during therapy treatments. The controller 170 may further include an input for a user/caregiver to set one or more target flow rates (TFR).
In some embodiments, the user/caregiver may set the target flow rates (TFR) as the switching condition for determining whether the dressing 115 or other components are in a high leakage state or a low leakage state. For example, if the flow rate (FR) is greater than the fixed target flow rate (TFR), i.e., a high leak condition, the bang-bang controller is disabled so that the PID controller takes over in order to keep the wound site pressure (WP) as close to the target wound site pressure (TP) as possible. However, if the flow rate (FR) is less than or equal to the fixed target flow rate (TFR), i.e., a low leak condition, the bang-bang controller is enabled to contain the wound site pressure (WP) within the differential wound site pressure (δWP) range while conserving battery power and reducing noise from the pressure pump 112. For example, the fixed target flow rate (TFR) may be 65 cc/min. As indicated above, it is desirable to keep the bang-bang controller running as much as possible during treatments when the dressing 115 is in a low leakage condition. For example, the system controller 170 may engage the bang-bang controller when the flow rate (FR) is less than or equal to the fixed target flow rate (TFR), but switch back to the PID controller when the flow rate (FR) is greater than the fixed target flow rate (TFR) as a result of additional leakage that develops in the dressing 115 because the patient moving around which ultimately creates a high leak condition.
In another embodiment, the bang-bang controller may have a dual target flow rate (TFR) capability wherein the system controller 170 further includes an input for a user to set two target flow rates (TFR) as switching conditions for determining whether the dressing 115 or other components are in a high leakage state or a low leakage state: an ascending target flow rate (TFRA) when the bang-bang controller is enabled with an increasing flow rate (FR) and a descending target flow rate (TFRD) when the PID controller is enabled with a decreasing flow rate (FR). In one embodiment, both the ascending target flow rate (TFRA) and the descending target flow rate (TFRD) are greater than the fixed target flow rate (TFR) so that the system controller 170 switches more quickly from the PID controller to the bang-bang controller and more slowly from the bang-bang controller to the PID controller. For example, the ascending target flow rate (TFRA) and the descending target flow rate (TFRD) may both be set to about 80 cc/min which is higher than the fixed target flow rate (TFR) of 65 cc/min in the previous example. In yet another embodiment, the ascending target flow rate (TFRA) may also be greater than the descending target flow rate (TFRD) so that the system controller 170 switches even more quickly from the PID controller to the bang-bang controller and even more slowly from the bang-bang controller to the PID controller. In this case, the system controller 170 favors the benefits derived from using the bang-bang controller as opposed to the deficiencies associated with the continuous operation of the PID controller. For example, the ascending target flow rate (TFRA) may be 75 cc/min and the descending target flow rate (TFRD) may be about 85 cc/min. If the PID controller is currently enabled in a high leak condition wherein the flow rate (FR) is decreasing, the descending target flow rate (TFRD) would be set at 85 cc/min rather than 65 cc/min so that the system controller 170 switches more quickly from the PID controller to enable the bang-bang controller. Alternatively, if the bang-bang controller is enabled in a low leak condition wherein the flow rate (FR) is increasing, the ascending target flow rate (TFRA) would be set at 75 cc/min rather than 65 cc/min so that the system controller 170 switches more slowly to disable the bang-bang controller.
In one embodiment, controller 170 may provide an output signal to the indicator 172 to emit a visual and/or audible signal in response to the wound site pressure (WP) at tissue site 105, as measured by first pressure sensor 155, being nonresponsive to increasing the pump pressure (PP). For example, the indicator 172 may be a light emitting diode (LED) that provides a visual signal. In this embodiment, indicator 172 illuminates in response to the wound site pressure (WP) at tissue site 105 being nonresponsive to an increasing pump pressure. In another embodiment, indicator 172 is a sound emitting device, such as a speaker. In this embodiment, indicator 172 emits a sound in response to the wound site pressure (WP) at tissue site 105 being nonresponsive to an increasing pump pressure. The controller 170 may provide other output signals indicating whether the negative-pressure therapy system is in a low or high leak condition.
Referring now to
The therapy algorithm 703 begins by determining whether the bang-bang controller is active or not at 713. If the PID controller is engaged and the bang-bang controller is not, a local pump pressure (PPL) is set at a current pump pressure (PPC) at 715. As described above, the PID control adjusts the applied voltage (VA) to the DC motor 114 to achieve a pump pressure (PP) between the minimum pump pressure value (PPmin) and the maximum pump pressure value (PPmax) to maintain the wound site pressure (WP) proximate the target wound site pressure (TP). Referring back to
When the wound site pressure (WP) drops too low in the descending mode, e.g., below the minimum wound site pressure value (WPmin) as described above, the pressure pump 112 is turned on with an applied voltage (VA) greater than the stall voltage, i.e., the bang-bang on voltage (VON), to increase the pump pressure (PP) to the maximum pump pressure (PPmax) in the ascending mode. The bang-bang on voltage (VON) continues to be applied until the pump pressure (PP) reaches the maximum pump pressure value (PPmax) as shown, for example, at 501 and 503, or the wound site pressure (WP) reaches the maximum wound site pressure value (WPmax) as shown, for example, at 502 and 504, whichever occurs first. When the wound site pressure (WP) is in the ascending mode, the therapy algorithm 703 sets the local target wound site pressure (TPL) at the target wound site pressure (TP) plus a hysteresis value (H) at 723. The hysteresis value (H) is the maximum amount of pressure that the wound site pressure (WP) should increase above the target wound site pressure (TP) when in the ascending mode before the bang-bang controller turns off the pressure pump 112 to protect the tissue site 105 from an excessive amount of reduced pressure that could be damaging. The hysteresis value (H) sets the upper limit above the target wound site pressure (TP) which is the maximum pressure value (WPmax). For example, if the hysteresis value (H) is 10 mmHg, the maximum wound site pressure value (WPmax) is set at 135 mmHg as shown in
Correspondingly, when the wound site pressure (WP) rises too high in the ascending mode, e.g., above the maximum wound site pressure value (WPmax) or the maximum pump pressure value (PPmax) as described above, the pressure pump 112 is turned off so that no pump pressure (PP) is applied allowing the residual pressure in the reduced pressure therapy system 100 to decrease in the descending mode as a result of the leakage in the system. The pressure pump 112 remains off until the wound site pressure (WP) is again less than or equal to the minimum wound site pressure value (WPmin) is shown, for example, at 508, or the pump pressure (PP) is less than or equal to the minimum pump pressure value (PPmin) as shown, for example, at 507, whichever occurs first. When the wound site pressure (WP) is in the descending mode as described above, the therapy algorithm 703 sets the local target wound site pressure (TPL) at the target wound site pressure (TP) minus the hysteresis value (H) at 721. The hysteresis value (H) is the minimum amount of pressure that the wound site pressure (WP) should decrease below the target wound site pressure (TP) when in the descending mode before the system controller 170 determines that the leakage rate (LR) has increased to a flow rate that is large enough to require the PID controller to maintain the wound site pressure (WP) closer to the target wound site pressure (TP) as described above. Thus, the hysteresis value (H) also sets the lower limit below the target wound site pressure (TP) which is the minimum pressure value (WPmin). For example, if the hysteresis value (H) is 10 mmHg, the minimum wound site pressure value (WPmin) is set at 115 mmHg as shown in
After the therapy algorithm 703 sets the DC motor voltage (VM) to equal the applied voltage (VA) at 709 to reenter the therapy loop 700, the therapy loop 700 then reads the current flow rate (FR) measured by the system controller 170 at 725 and determines whether or not the current flow rate (FR) is less than the target flow rate (TFR) at 727. If the flow rate (FR) is less than the target flow rate (TFR) indicating a low leakage condition as described above, then the bang-bang controller stays on or is enabled as indicated at 729. However, if the flow rate (FR) is greater than or equal to the target flow rate (TFR) indicating a high leakage condition as described above, then the bang-bang controller stays off or is disabled as indicated at 731. Finally, the therapy loop 700 checks to see if the negative-pressure wound therapy system 100 has been turned off at 733 and, if not, continues the therapy loop as indicated at 735. If the negative-pressure therapy system 100 has been turned off, the therapy loop ends at 737.
The systems, apparatuses, and methods described herein may provide significant advantages. For example, PID control algorithms constantly adjust a negative-pressure source to maintain pressure within a specified tolerance, which can be inefficient in low-leak applications, drawing more power than a simple hysteresis control algorithm. Conversely, a hysteresis algorithm can work well in low-leak applications and uses relatively little power, but can cause a negative-pressure source to turn off and on frequently in high-leak applications, which can be noisy and increase power consumption. Hybrid control, as described herein, can combine the benefits of PID and hysteresis control algorithms to minimize power consumption and noise. If a negative-pressure therapy application has a low-leak, for example, a hybrid control algorithm can select a hysteresis control algorithm to minimize power consumption. If the application changes or develops a higher leak, a hybrid control algorithm can switch to a PID control algorithm to minimize noise.
Referring now to
The provision of negative-pressure therapy with negative-pressure therapy systems is increasingly being performed with smaller therapy device 100 that use batteries to provide power to a pump 112 rather than a connection to an electrical outlet. Use of batteries decreases the total power supply available to the therapy device 100. As a result, power drains that would be considered negligible in a therapy device 100 powered through an electrical outlet connection may significantly reduce the ability of the therapy device 100 to provide therapy for the duration of the therapeutic life cycle. A power drain refers to operation of the therapy device that requires use of electrical power, for example, operation of a pump 112 to generate reduced pressure. Power drains may be caused by low-level dressing leaks, for example, a low-level dressing leak can drain power from a battery of a therapy device 100 by repeatedly triggering operation of the therapy device 100 to maintain the necessary reduced pressure at the tissue site. These power drains shorten the useful life of the therapy device 100 before disposal of the therapy device 100, recharge of the battery, or battery replacement is required. Leak detection techniques may help to identify some leaks that may be then sealed by the user; however, low level leaks will challenge the most sensitive leak detection systems and may often go undetected.
In an example embodiment, the therapy device 100 may be a small portable disposable therapy device 100 powered by batteries and either a user/clinician may configure the system controller 170 for a 7-day (168-hour) therapeutic life cycle or the therapy device 100 may be preconfigured during manufacture for a 7-day therapeutic life cycle. The system controller 170 may further be configured to determine via a clock, counter, timer or the like how much of the therapeutic life cycle has been completed to date and thereby determine the balance of the therapeutic life cycle that has yet to be competed 810. The duration of the therapeutic life cycle may also be modified by the clinician in real time, for example, the system controller 170 may be reconfigured by the clinician for an 8-day (192-hour) therapeutic life cycle.
The therapy algorithm 803 may use the balance and/or a change in the balance of the therapeutic life cycle in its analysis. For instance, it may be preferable to compete the therapeutic life cycle with a wide hysteresis control band rather than attempt to maintain a narrow hysteresis control band and fail to compete the therapeutic life cycle because the batteries have insufficient capacity to do so. The therapy algorithm 803 may be configured with this information and make its determination whether to switch to a narrow hysteresis control band or a wider hysteresis control band based upon, at least in part, the balance of the therapeutic life cycle or how much of the existing therapeutic life cycle it has yet to complete.
The therapy algorithm 803 may further read current battery charge level (BCL) as determined by the system controller 170 at 820. When the current battery charge level (BCL) is less than a first target charge level (TCL1) 836, which may indicate a low battery charge level in the system, the system controller 170 may be configured to select a wide hysteresis control band 860, alternatively when the current battery charge level (BCL) is greater than a second target battery charge level (TCL2) 832, which may indicate a high battery charge level in the system, the system controller 170 may be configured to select a narrow hysteresis control band 850. The first target charge level (TCL1) may be less than the second target charge level (TCL2) alternatively the first target battery charge level (TCL1) may be substantially equal to the second target battery charge level (TCL2). The battery charge level (BCL) may be determined using known electronic circuits.
In some embodiments, a low battery charge level may also indicate a high-leakage condition in the system and/or a high battery charge level may also indicate a low-leakage condition in the system. In some instances the therapy algorithm 803 may further determine whether the batteries have been replaced, the batteries have been recharged or an existing leak in the system has been addressed during the therapeutic life cycle.
In some embodiments, the system controller 170 may be configured to alternatively select the narrow hysteresis control band 850 when the battery charge level in the system is high or the wide hysteresis control band 860 when the battery charge level in the system is low.
In some embodiments, the TCL1 value and/or the TCL2 value may be based upon, at least in part, the balance of the therapeutic life cycle and may therefore be dynamic. For example, as the balance of the therapeutic life cycle decreases with time so may the values of TCL1 and/or TCL2 decrease with time.
The therapy algorithm 803 may further the read the current flow rate (FR) of fluid between the pump and the porous pad as determined by the system controller 170 at 836. When the current flow rate (FR) is less than a first target flow rate (TFR1) 842, which may indicate a low-leakage condition in the system, the system controller 170 may be configured to select a narrow hysteresis control band 850, alternatively when the current flow rate (FR) is greater than a second target flow rate (TFR2) 840, which may indicate a high-leakage condition in the system, the system controller 170 may be configured to select a wide hysteresis control band 860. The first target flow rate (TFR1) may be less than the second target flow rate (TFR2) alternatively the first target flow rate (TFR1) may be substantially equal to the second target rate (TFR2). The current flow rate (FR) or leak rate may be inferred from the duty cycle of the pressure pump 112 and the duty cycle may be determined using know electronic circuits.
In some embodiments, the system controller 170 may be configured to alternatively select the narrow hysteresis control band 850 when the system is determined to be in a low-leak condition state or the wide hysteresis control band 860 if the system is determined to be in a high-leakage condition state. While, the alternative selection of either the narrow hysteresis control band 850 or wide hysteresis control band 860 has been discussed in the context of conserving battery power there may be other considerations. For example, the system controller 170 may be configured select a hysteresis control band with a tighter set of limits at the initiation of the therapeutic life cycle for the purpose of achieving and maintaining a therapeutic seal whilst the bonding agents of the dressing activates, after which the system may select a hysteresis control band with looser set of limits.
In some embodiments, the TFR1 value and/or the TFR2 value may be based upon, at least in part, the balance of the therapeutic life cycle and may therefore be dynamic. For example, as the balance of the therapeutic life cycle decreases with time so may the values of TFR1 and/or TFR2 decrease with time.
While the therapy algorithm 803 is described herein as having only a narrow hysteresis control band and wide hysteresis control band this is intended to be for illustration purposes only, as will be understood by a person having ordinary skill in the art, there may be more than two hysteresis control bands additionally/alternatively there may be one hysteresis control band and the size of the one or more hysteresis control band(s) may be dynamically varied based upon, at least in part, the balance of the therapeutic life cycle, the current battery charge level (BCL) and the current flow rate (FR).
In some embodiments, the balance of the therapeutic life cycle, the current battery charge level (BCL) and the current flow rate (FR) may be each be weighted and the therapy algorithm 803 may be configured to alternatively select the narrow hysteresis control band 850 or the wide hysteresis control band 860 based upon, at least in part, a determination of a weighted score.
Since, the therapy algorithm 803 utilizes a minimum wound site pressure (WPMin) it will have the added advantage of assisting the pressure pump 112 to restart against an existing system pressure. As stated above it is more difficult for the pressure pump 112 to restart against an existing system pressure and this may be exacerbated by a low battery charge level (BCL) and a corresponding decrease in battery terminal voltage. By utilizing a minimum wound site pressure (WPMin) this restriction may be eased because once the pressure pump 112 has gained momentum it may be able to then reach a higher maximum wound site pressure (WPMax), than it would otherwise have been able to with the current battery charge level (BCL)/battery terminal voltage.
In some embodiments, the therapy algorithm 803 may be a master algorithm, for example, if the system controller 170 includes both the PID controller and the bang-bang controller, i.e., a hybrid controller and/or a therapy algorithm 703 as described above any conflict between the two may be determined by the therapy algorithm 803. For example, while the therapy algorithm 703 may be configured to engage the bang-bang controller when the flow rate (FR) is less than or equal to the fixed target flow rate (TFR), but switch back to the PID controller when the flow rate (FR) is greater than the fixed target flow rate (TFR) this may be overridden by the therapy algorithm 803 based upon power consumption considerations rather than maintaining a target pressure (TP) in high leakage systems.
In some embodiments, the PID controller may be configured to have a hysteresis control band as described herein and the PID controller will send power to the DC motor 114 only when the wound site pressure (WP) has decayed to the minimum wound site pressure (WPMin) and the power to the DC motor 114 may also be decreased as it approaches the target pressure (TP). While the proposed therapy algorithm 803 has been described in terms of modifying and/or selecting 850, 860 hysteresis control bands its will be approached that it could equally have been described in terms of altering the minimum wound site pressure (WPMin), the maximum wound site pressure (WPMax), the differential wound site pressure range (δWP) or the differential pump pressure range (δPP) to maximize efficiency based upon, at least in part, the measurement of the power available, the leak into the system and the balance of the therapeutic life cycle.
While, the illustrative embodiments are for a negative-pressure wound treatment system the system and methods described herein are applicable for other medical and non-medical systems where a pump is used and there would be a benefit to adjusting the control bands of the pump to improve system efficiency.
Further, while shown in a few illustrative embodiments, a person having ordinary skill in the art will recognize that the systems, apparatuses, and methods described herein are susceptible to various changes and modifications. Moreover, descriptions of various alternatives using terms such as “or” do not require mutual exclusivity unless clearly required by the context, and the indefinite articles “a” or “an” do not limit the subject to a single instance unless clearly required by the context.
The appended claims set forth novel and inventive aspects of the subject matter described above, but the claims may also encompass additional subject matter not specifically recited in detail. For example, certain features, elements, or aspects may be omitted from the claims if not necessary to distinguish the novel and inventive features from what is already known to a person having ordinary skill in the art. Features, elements, and aspects described herein may also be combined or replaced by alternative features serving the same, equivalent, or similar purpose without departing from the scope of the invention defined by the appended claims.
This application claims the benefit, under 35 USC § 119(e), of the filing of U.S. Provisional Patent Application Ser. No. 62/467,683, entitled “System And Method For Improving Battery Life Of Portable Negative-Pressure Therapy Through Hysteresis Control” filed Mar. 6, 2017, which is incorporated herein by reference for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2018/017351 | 2/8/2018 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62467683 | Mar 2017 | US |
